Could the answer to treating a rare childhood brain disorder be hiding behind some whiskers? Underlying this unlikely connection is a shared genetic malfunction that affects both feline and human brains in strikingly similar ways. Researchers are turning to cats to unravel the mysteries of GM1 gangliosidosis, a devastating genetic disease that robs children of movement, cognition, and, ultimately, life.
Dr. Heather Gray-Edwards, an assistant professor of radiology at UMass Chan Medical School, has been studying gene therapy for GM1 gangliosidosis and similar genetic diseases for several years. Her work focuses on developing viral vector-based treatments — using harmless viruses to deliver a working copy of the defective gene directly into brain and spinal cord cells — to restore enzyme activity and prevent the buildup of toxic molecules that damage neurons. “Cats really mimic the disease in humans almost exactly, both in onset and symptoms,” Gray-Edwards says. “That’s what’s magical about being able to study the large animals — you can really predict what’s going to happen in the clinic to a better degree than with rodents.”
Unlike mice, which are often engineered to model disease, cats can spontaneously develop GM1 due to naturally occurring mutations in the same gene (GLB1) that causes the disorder in children. Kittens show tremors, difficulty swallowing, and weakness within weeks of birth. As the disease progresses, they decline both physically and cognitively, closely resembling the children who suffer from the severe infantile form. Because the disease unfolds quickly in cats, scientists can observe its full course in months rather than years — an invaluable advantage for testing new treatments.
Only after researchers noticed this uncanny similarity did they step back to study what’s happening inside the body. In those suffering from GM1, a single faulty gene breaks the cell’s recycling system. Normally, an enzyme called beta-galactosidase clears away fatty waste molecules. But without the enzyme, that waste piles up inside neurons until the cells swell, choke, and die. Since brain cells are particularly vulnerable, the nervous system takes the hardest hit. For families, that translates into children who appear healthy at birth but soon lose motor skills, suffer seizures, and decline rapidly. With no cure, most infants live only a few years.
- GM1 gangliosidosis is a rare, inherited, and fatal neurodegenerative disease in children.
- Cats naturally develop the same genetic mutation, exhibiting symptoms and disease progression similar to humans.
- Gene therapy uses viral vectors to deliver a functional copy of the defective gene into the brain and spinal fluid.
- Treated cats show improved enzyme activity, reduced toxic buildup, and extended lifespan, informing early human clinical trials.
For decades, treatment options have been frustratingly limited. Enzyme replacement therapy has worked in some related disorders, but in GM1, it cannot cross into the brain. Drugs called pharmacological chaperones, which help stabilize and rescue misfolded enzymes, have been tested with modest results, according to a 2009 study published in Perspectives in Medicinal Chemistry. Families rely mainly on supportive care.
Gene therapy, however, is changing the picture. Gray-Edwards and her team are testing an approach that uses viral vectors to deliver a healthy copy of the defective gene directly into the brain and spinal fluid. Once inside, neurons can begin producing the missing enzyme themselves. Treated cats show striking improvements: less buildup of toxic molecules, healthier brain tissue, and better motor control. In 2016, Gray-Edwards (publishing under her maiden name “Edwards”) reported in Molecular Therapy that while untreated GM1 cats live to about 6 months, many treated cats were still alive at 5 to 6 years of age.“We looked at the cat model, the data that came out,” Gray-Edwards says. “It matched what we saw preclinically almost perfectly, where one was way more effective than the other one.”
Because the disease in cats so closely mirrors the human form, these studies help researchers refine dosage, delivery, and safety — and they’ve already informed early-stage clinical trials now underway in children with GM1 gangliosidosis. The short feline lifespan also accelerates long-term data collection while still capturing quality-of-life outcomes like learning and social behavior.
Still, this work is not without its challenges. Cats don’t replicate every aspect of human biology, and ethical concerns weigh heavily. “We have to remember these are sentient beings who are suffering from a terrible disease,” Gray-Edwards says. “It’s our responsibility to make sure that every study is justified, humane, and ultimately aimed at alleviating suffering — in animals and in children.”
What begins in the laboratory with kittens may one day give children facing GM1 something they’ve never had before: a real chance at slowing or even stopping the disease. “What’s really powerful is that what we learn from these animals goes right back to helping children,” Gray-Edwards says. “It’s all connected.”
Sources
Concolino, D., Deodato, F., & Parini, R. (2018). Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr 44(Suppl 2), 120. https://doi.org/10.1186/s13052-018-0562-1
Edwards, H., Randle, A., Sena-Esteves, M., & Martin, D. (2016). 361. IV gene therapy corrects feline GM1 gangliosidosis long term. Mol Ther, 24, (Suppl 1) S144–S145. https://doi.org/10.1016/s1525-0016(16)33170-7
Foster, D., Williams, L., Arnold, N., & Larsen, J. (2024). Therapeutic developments for neurodegenerative GM1 gangliosidosis. Front Neurosci, 18, 1392683. https://doi.org/10.3389/fnins.2024.1392683
Gray-Edwards, Heather. Interview conducted by Dhaeshna Booma. September 16, 2025.
Gray-Edwards, H. L., Regier, D. S., Shirley, J. L., Randle, A. N., Salibi, N., Thomas, S. E., Latour, Y. L., Johnston, J., Golas, G., Maguire, A. S., Taylor, A. R., Sorjonen, D. C., McCurdy, V. J., Christopherson, P. W., Bradbury, A. M., Beyers, R. J., Johnson, A. K., Brunson, B. L., Cox, N. R., . . . Martin, D. R. (2017). Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Mol Ther, 25(4), 892–903. https://doi.org/10.1016/j.ymthe.2017.01.009
Gross, A. L., Gray-Edwards, H. L., Bebout, C. N., Ta, N. L., Nielsen, K., Brunson, B. L., Mercado, K. R. L., Osterhoudt, D. E., Batista, A. R., Maitland, S., Seyfried, T. N., Sena-Esteves, M., & Martin, D. R. (2021). Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis. Brain, 145(2), 655–669. https://doi.org/10.1093/brain/awab309
National Institutes of Health Clinical Trials (updated 2025). Gene transfer vector Rh.10 for children with GM1 gangliosidosis (ClinicalTrials.gov Identifier: NCT03952637). https://clinicaltrials.gov/ct2/show/NCT03952637
Suzuki, Y., Ogawa, S., & Sakakibara, Y. (2009). Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Med Chem, 3, 7–19. https://doi.org/10.4137/pmc.s2332
Takai, T., Higaki, K., Aguilar-Moncayo, M., Mena-Barragán, T., Hirano, Y., Yura, K., Yu, L., Ninomiya, H., García-Moreno, M. I., Sakakibara, Y., Ohno, K., Nanba, E., Mellet, C. O., Fernández, J. M., & Suzuki, Y. (2013). A bicyclic 1-Deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther, 21(3), 526–532. https://doi.org/10.1038/mt.2012.263
Editorial Team
- Chief Editors: Chloe Eng, Aanya Bulusu
- Associate Editor: Eric Yang
- Team Editor: Ananya Datta
- Graphic Designer: Audrey Hosmer
- Social Media Coordinators: Abigail Marquez, Andy Alvarado Rodriguez
- Web Manager: Ananya Datta
Mentor
- Noah Frank is a local and national award-winning journalist and communications professional with more than 15 years of experience in print, digital, social and broadcast media. He is the lead writer and media relations contact for Virginia Tech in the D.C. area, with a heavy focus on research in AI, wireless technologies, cybersecurity, and quantum computing.
Content Expert
Heather Gray-Edwards, D.V.M., Ph.D., is an Assistant Professor of Radiology at UMass Chan Medical School and a principal investigator at the Horae Gene Therapy Center. She studies neurodegenerative diseases in large animals, including GM1 and GM2 gangliosidosis and Tay-Sachs disease. Her research focuses on MRI-based tracking of disease progression and testing adeno-associated-virus gene therapies to restore enzyme activity and prevent neuronal damage.
